NASDAQ:PRVB

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)

Retrieved on: 
Monday, March 13, 2023
PFE, HNI Corporation, SNY, NYSE, Pfizer, Tripura Merger Agreement, Qualtrics, Brodsky, Silver, HNI, Security (finance), Sanofi, Seagen

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Silver Lake will pay $18.15 in cash for each share of Qualtrics common stock in a deal valued at approximately $12.5 billion.
  • Kimball shareholders will receive $9.00 in cash and 0.1301 shares of HNI common stock for each share of Kimball common stock they own.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB

Retrieved on: 
Monday, March 13, 2023
Class Action Lawsuit, Professional Services, Legal, KSF, Sale, Sanofi

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Provention Bio, Inc. (NasdaqGS: PRVB) to Sanofi (NasdaqGS: SNY).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Provention Bio, Inc. (NasdaqGS: PRVB) to Sanofi (NasdaqGS: SNY).
  • Under the terms of the proposed transaction, shareholders of Provention will receive only $25.00 in cash for each share of Provention that they own.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

PRVB STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Provention Bio, Inc. Is Fair to Shareholders

Retrieved on: 
Monday, March 13, 2023
Legal, Professional Services, Advertising, Fraud, Sale, Security (finance), Sanofi

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Provention Bio, Inc. (NASDAQ: PRVB) to Sanofi for $25.00 per share in cash is fair to Provention shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Provention Bio, Inc. (NASDAQ: PRVB) to Sanofi for $25.00 per share in cash is fair to Provention shareholders.
  • On behalf of Provention shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Provention Bio Announces the Grant of Inducement Awards

Retrieved on: 
Friday, March 3, 2023
BANK, RED, Employment

RED BANK, N.J., March 3, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to a new  non-executive employee to purchase an aggregate of 10,000 shares of common stock.

Key Points: 
  • RED BANK, N.J., March 3, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to a new  non-executive employee to purchase an aggregate of 10,000 shares of common stock.
  • The stock options were granted without stockholder approval as inducements, material to the new non-executive employee entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation committee of the board of directors.
  • The stock options were granted with a 10-year term and an exercise price equal to $8.39 the closing price per share of the Company's common stock as reported by Nasdaq on March 1st, 2023.
  • The stock options are subject to the terms of the Provention Bio, Inc. 2020 Inducement Plan, as amended.

Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

Retrieved on: 
Thursday, February 23, 2023
BANK, RED, Cryptocurrency, Broadcasting

RED BANK, N.J., Feb. 23, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023, before the opening of the U.S. financial markets.

Key Points: 
  • RED BANK, N.J., Feb. 23, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023, before the opening of the U.S. financial markets.
  • Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a corporate update.
  • To access the call, please dial 1-888-347-7861 (domestic) or 1-412-902-4247 (international) ten minutes prior to the start time and ask to be connected to the "Provention Bio Call."
  • An audio webcast will also be available on the "Events and Webcasts" page of the Investors section of the Company's website, www.proventionbio.com .

Provention Bio to Present at the SVB Securities Global Biopharma Conference

Retrieved on: 
Wednesday, February 8, 2023
BANK, Webcast, RED, Conference, Cryptocurrency, Broadcasting, Online shopping

RED BANK, N.J., Feb. 8, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will participate in a fireside chat presentation at the SVB Securities Global Biopharma Conference on Wednesday, February 15th, 2023 at 11:20am EST.

Key Points: 
  • RED BANK, N.J., Feb. 8, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will participate in a fireside chat presentation at the SVB Securities Global Biopharma Conference on Wednesday, February 15th, 2023 at 11:20am EST.
  • The presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events .
  • The webcast will be archived on the Company's website for 30 days following the presentation.

Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors

Retrieved on: 
Thursday, January 5, 2023
AbbVie, Akebia, Nephrology, Abbott, Pain, Biotechnology, Shire (pharmaceutical company), Therapy, Drug development, Divisional Railway Hospital, Golden Rock, Pharmacia & Upjohn, North Shore University Hospital, Inflammation, Health, The Stony Brook School, BANK, Abbott Laboratories, Amgen, Acquisition, G.D. Searle, LLC, Arthritis, State university system, FDA, Laboratory, Pharmacia, Senior, RED, Metabolism, Pharmaceutical industry, Pfizer, Medicine, Biology

RED BANK, N.J., Jan. 5, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Rita Jain, M.D., to the Company's Board of Directors.

Key Points: 
  • RED BANK, N.J., Jan. 5, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Rita Jain, M.D., to the Company's Board of Directors.
  • "Rita brings extensive drug development experience to Provention Bio across a wide range of therapeutic areas including autoimmune and metabolic diseases," said Wayne Pisano, Chairman of the Board of Provention Bio.
  • Dr. Jain, a board-certified rheumatologist, currently serves as a member of the supervisory board of AM Pharma and previously served on the Board of Directors of ChemoCentryx, Inc. until its acquisition by Amgen.
  • Earlier in her career, Dr. Jain served as a faculty member at North Shore University Hospital in New York.